Nimble Therapeutics Partners with Genentech to Discover and Develop Novel Peptide-Based Therapeutics

Nimble Therapeutics, a platform to synthesize and systematically discover novel medicines announced a multi-year collaboration with Genentech, a member of the Roche Group to boost discovery and developments of novel peptide-based medicines for targets across a range of diseases.

Jigar Patel, Ph.D, CEO, Nimble Therapeutics, states, “We are excited to collaborate with a world-class and well-respected organization such as Genentech to identify novel peptide therapeutics. This partnership combines the strengths of our two organizations to potentially bring new medicines to patients”.

The partnership will influence Nimble’s proprietary peptide synthesis, screening and optimization platform, chemical diversity, and integrated suite of assays to enable faster discovery and optimization of promising compounds for intracellular and extracellular targets. Under the terms of the agreement, Nimble will be receiving an undisclosed upfront payment and will be eligible for downstream milestone payments and royalties.

Headquartered in Madison, Nimble Therapeutics enables the rapid synthesis, screening of millions of scaffolded natural and modified macrocyclic peptidomimetics. The company will be developing partnerships with leading pharmaceutical companies to power its technology across many therapeutic areas.

Read More News :

Facebook Invests in Indian Education Start-up Unacademy

Infosys Join Hands with GE Appliances to Boost Digital and Workplace Transformation